45 related articles for article (PubMed ID: 28562428)
21. Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients.
Saldivar JS; Lu KH; Liang D; Gu J; Huang M; Vlastos AT; Follen M; Wu X
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S223-9. PubMed ID: 17825393
[TBL] [Abstract][Full Text] [Related]
22. BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer - an observational cohort study.
Unni SK; Schauerhamer MB; Deka R; Tyczynski JE; Fernandes AW; Stevens V; Brixner DI; Stenehjem DD
J Ovarian Res; 2016 Mar; 9():18. PubMed ID: 27004793
[TBL] [Abstract][Full Text] [Related]
23. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
[TBL] [Abstract][Full Text] [Related]
24. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
[TBL] [Abstract][Full Text] [Related]
26. A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Chung CH; Lee JW; Slebos RJ; Howard JD; Perez J; Kang H; Fertig EJ; Considine M; Gilbert J; Murphy BA; Nallur S; Paranjape T; Jordan RC; Garcia J; Burtness B; Forastiere AA; Weidhaas JB
Ann Oncol; 2014 Nov; 25(11):2230-2236. PubMed ID: 25081901
[TBL] [Abstract][Full Text] [Related]
27. SET-NUP214 is a recurrent γδ lineage-specific fusion transcript associated with corticosteroid/chemotherapy resistance in adult T-ALL.
Ben Abdelali R; Roggy A; Leguay T; Cieslak A; Renneville A; Touzart A; Banos A; Randriamalala E; Caillot D; Lioure B; Devidas A; Mossafa H; Preudhomme C; Ifrah N; Dombret H; Macintyre E; Asnafi V
Blood; 2014 Mar; 123(12):1860-3. PubMed ID: 24449214
[TBL] [Abstract][Full Text] [Related]
28. Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib.
Arcaroli JJ; Quackenbush KS; Powell RW; Pitts TM; Spreafico A; Varella-Garcia M; Bemis L; Tan AC; Reinemann JM; Touban BM; Dasari A; Eckhardt SG; Messersmith WA
Clin Cancer Res; 2012 May; 18(9):2704-14. PubMed ID: 22553375
[TBL] [Abstract][Full Text] [Related]
29. Nuclear export of proteins and drug resistance in cancer.
Turner JG; Dawson J; Sullivan DM
Biochem Pharmacol; 2012 Apr; 83(8):1021-32. PubMed ID: 22209898
[TBL] [Abstract][Full Text] [Related]
30. Alterations in nuclear pore architecture allow cancer cell entry into or exit from drug-resistant dormancy.
Kinoshita Y; Kalir T; Rahaman J; Dottino P; Kohtz DS
Am J Pathol; 2012 Jan; 180(1):375-89. PubMed ID: 22074739
[TBL] [Abstract][Full Text] [Related]
31. An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity.
Wynendaele J; Böhnke A; Leucci E; Nielsen SJ; Lambertz I; Hammer S; Sbrzesny N; Kubitza D; Wolf A; Gradhand E; Balschun K; Braicu I; Sehouli J; Darb-Esfahani S; Denkert C; Thomssen C; Hauptmann S; Lund A; Marine JC; Bartel F
Cancer Res; 2010 Dec; 70(23):9641-9. PubMed ID: 21084273
[TBL] [Abstract][Full Text] [Related]
32. Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer: a meta-analysis.
Hess LM; Rong N; Monahan PO; Gupta P; Thomaskutty C; Matei D
Cancer; 2010 Nov; 116(22):5251-60. PubMed ID: 20665885
[TBL] [Abstract][Full Text] [Related]
33. Cancer statistics, 2009.
Jemal A; Siegel R; Ward E; Hao Y; Xu J; Thun MJ
CA Cancer J Clin; 2009; 59(4):225-49. PubMed ID: 19474385
[TBL] [Abstract][Full Text] [Related]
34. The nuclear pore component Nup358 promotes transportin-dependent nuclear import.
Hutten S; Wälde S; Spillner C; Hauber J; Kehlenbach RH
J Cell Sci; 2009 Apr; 122(Pt 8):1100-10. PubMed ID: 19299463
[TBL] [Abstract][Full Text] [Related]
35. Clinical update: novel targets in gynecologic malignancies.
Aghajanian C
Semin Oncol; 2004 Dec; 31(6 Suppl 16):22-6; discussion 33. PubMed ID: 15799241
[TBL] [Abstract][Full Text] [Related]
36. Chemotherapy for early ovarian cancer.
Trimbos JB; Timmers P
Curr Opin Obstet Gynecol; 2004 Feb; 16(1):43-8. PubMed ID: 15128007
[TBL] [Abstract][Full Text] [Related]
37. Depletion of a single nucleoporin, Nup107, prevents the assembly of a subset of nucleoporins into the nuclear pore complex.
Boehmer T; Enninga J; Dales S; Blobel G; Zhong H
Proc Natl Acad Sci U S A; 2003 Feb; 100(3):981-5. PubMed ID: 12552102
[TBL] [Abstract][Full Text] [Related]
38. Domain-specific antibodies reveal multiple-site topology of Nup153 within the nuclear pore complex.
Fahrenkrog B; Maco B; Fager AM; Köser J; Sauder U; Ullman KS; Aebi U
J Struct Biol; 2002; 140(1-3):254-67. PubMed ID: 12490173
[TBL] [Abstract][Full Text] [Related]
39. The nucleoporin CAN/Nup214 binds to both the cytoplasmic and the nucleoplasmic sides of the nuclear pore complex in overexpressing cells.
Boer JM; van Deursen JM; Croes HJ; Fransen JA; Grosveld GC
Exp Cell Res; 1997 Apr; 232(1):182-5. PubMed ID: 9141635
[TBL] [Abstract][Full Text] [Related]
40. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
N Engl J Med; 1996 Jan; 334(1):1-6. PubMed ID: 7494563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
